Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.
Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at [email protected]
CAR T Cell Functionality Correlates With Outcomes, Offering a Biomarker for Response
April 4th 2017The flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma, according to a retrospective analysis presented at the 2017 AACR Annual Meeting.
FDA Grants Priority Review to CTL019 for ALL
March 30th 2017The FDA has granted a priority review designation to tisagenlecleucel-T as a treamtnet for pediatric and young adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia, making it the first CAR T-cell therapy to enter regulatory review.
KTE-C19 Response Rates Spark FDA Submission for Aggressive Lymphomas
December 6th 2016Treatment with the CD19-directed CAR T-cell therapy KTE-C19 showed a complete remission rate of 73% for patients with aggressive, chemorefractory primary mediastinal B-cell lymphoma and transformed follicular lymphoma.
CTL019 Highly Effective in Global Phase II ALL Study, FDA Submission Anticipated
December 4th 2016The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
FDA Lifts Clinical Hold on Phase II Trial of JCAR015 in ALL
July 13th 2016After less than a week, the FDA has lifted a clinical hold placed on the phase II ROCKET study that is exploring the CAR T-cell therapy JCAR015 for adult patients with relapsed or refractory B cell acute lymphoblastic leukemia.
FDA Grants Nivolumab Breakthrough Designation for Head and Neck Cancer
April 25th 2016The FDA has granted a breakthrough therapy designation to nivolumab as a single-agent treatment for patients with recurrent or metastatic squamous cell carcinoma of the head and neck following a platinum-based therapy.
Nivolumab Doubles 1-Year OS Rates in Head and Neck Cancer
April 19th 2016Treatment with single-agent nivolumab reduced the risk of death by 30% and double 1-year overall survival rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.
CAR T-cells Rapidly Evolving as Cancer Therapies
March 20th 2016Chimeric antigen receptor-modified T-cell therapies have demonstrated durable complete responses for patients with relapsed/refractory B-cell acute lymphoblastic leukemia; however, several questions remain regarding their optimal use and applicability outside of this disease.
Second-Line Cabozantinib Shows Rare Survival Advantage in RCC
February 1st 2016The second interim analysis of the phase III METEOR trial has revealed a statistically significant improvement in overall survival with cabozantinib (Cometriq) versus everolimus as a treatment for patients with advanced renal cell carcinoma following progression on one prior therapy.
Allogeneic CAR T-Cell Therapy Shows Promising Efficacy Without GVHD
January 29th 2016Treatment with allogeneic anti–CD19 chimeric antigen receptor–modified T cell therapy induced complete remissions in 30% of patients with advanced progressive B-cell malignancies without causing graft-versus-host disease.
Lenvatinib/Everolimus Combo Submitted for Approval in Advanced RCC
January 15th 2016Regulatory filings have been submitted in the United States and Europe for the combination of lenvatinib and everolimus as a treatment for patients with metastatic renal cell carcinoma following a VEGF-targeted therapy.